60 completed, 29 unknown, 8 terminated, 4 withdrawn. 28 Not applicable, 23 Phase 2, 18 Phase 3, 18 Phase 4, 7 Phase 1.
Follow Proliferative Diabetic Retinopathy: new trials by email Literature Review of Proliferative Diabetic Retinopathy trials Research Report on Proliferative Diabetic Retinopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP. PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab - Proliferative Diabetic Retinopathy, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Southeast Retina Center, Georgia | 20 | 2026-09-01 | 2026-10-13 |
| New Pattern of Retinal Laser Treatment for PDR A new pattern of retinal laser - Proliferative Diabetic Retinopathy, Photocoagulation Burn to Retina | Not applicable | Not yet recruiting | Eye & ENT Hospital of Fudan University | 300 | 2026-01-01 | 2026-01-20 |
| UNITY VCS Vitreoretinal Surgery UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vision System, Vitreoretinal ophthalmic surgery - Epiretinal Membrane, Macular Hole | Not applicable | Withdrawn | Alcon Research | 2026-01-01 | 2025-12-12 | |
| Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy Single-session panretinal PRP (SS-PRP), Multiple-session panretinal PRP (MS-PRP) - Proliferative Diabetic Retinopathy, Diabetic Retinopathy | Not applicable | Recruiting | Vastra Gotaland Region | 40 | 2025-01-01 | 2025-11-18 |
| Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection conbercept ophthalmic injection （0.5mg）, Faricimab - Proliferative Diabetic Retinopathy | Not applicable | Completed | Bojie Hu | 8 | 2024-12-01 | 2025-08-28 |
| OCT and OCT-A Afer Diabetic Vitrectomy in PDR OCT and OCT-A - Proliferative Diabetic Retinopathy | Unknown | Assiut University | 30 | 2023-08-01 | 2023-07-10 | |
| Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia Peribulbar anesthesia with 0.5% bupivacaine and 2% lidocaine, Tetracaine 5% drops - Proliferative Diabetic Retinopathy | Phase 4 | Completed | Asociación para Evitar la Ceguera en México | 50 | 2023-07-06 | 2026-07-14 |
| VISUPRIME® Eye Drops VISUPRIME, Placebo - Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation | Not applicable | Completed | VISUfarma SpA | 78 | 2023-06-22 | 2024-07-19 |
| Outcomes of Retinal Re-surgeries in Silicone Oil Filled Eyes Resurgery In Silicone Oil Filled Eyes - Retinal Detachment, Proliferative Vitreo-Retinopathy | Completed | Ahalia Foundation Eye Hospital | 33 | 2023-01-01 | 2024-09-25 | |
| Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients Proliferative Diabetic Retinopathy, Pars Plana Vitrectomy | Unknown | Tianjin Medical University Eye Hospital | 250 | 2022-11-10 | 2022-11-30 | |
| Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy OPL-0401 Dose 1, Placebo - Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy | Phase 2 | Unknown | Valo Health, Inc. | 114 | 2022-08-16 | 2024-06-17 |
| Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy beveled 27G+ vitrectomy system, standard 25G+ vitrectomy system - Proliferative Diabetic Retinopathy, Vitrectomy | Not applicable | Completed | Tianjin Medical University Eye Hospital | 52 | 2022-07-11 | 2023-06-06 |
| Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use - Proliferative Diabetic Retinopathy | Phase 2 | Unknown | Peking University Third Hospital | 80 | 2022-04-01 | 2022-12-14 |
| Anti-VEGF in Real-world Ranibizumab, Aflibercept, Conbercept - Neovascular Age-related Macular Edema, Diabetic Macular Edema | Unknown | Wenbin Wei | 1000 | 2022-01-01 | 2022-02-03 | |
| A Study on the Treatment Strategy of NVG Secondary to PDR anti-VEGF - Neovascular Glaucoma, Proliferative Diabetic Retinopathy | Not applicable | Completed | Ruijin Hospital | 39 | 2021-12-12 | 2023-08-21 |
| Discovering Early Biomarkers in Circulating Endothelial Cells for Diabetes Complications by Single Cell RNA Sequencing Diabetes, Diabetes Mellitus | Completed | Aarhus University Hospital | 40 | 2021-12-08 | 2024-08-20 | |
| Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR preoperative group and intraoperative group - Proliferative Diabetic Retinopathy | Not applicable | Completed | Peking University People's Hospital | 102 | 2021-09-01 | 2022-06-07 |
| Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy preoperative intravitreal injections of ranibizumab or conbercept - Proliferative Diabetic Retinopathy | Not applicable | Completed | Peking University People's Hospital | 80 | 2021-09-01 | 2022-06-10 |
| Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy Bevacizumab Injection, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation - Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression | Phase 4 | Completed | Cairo University | 43 | 2021-03-30 | 2024-01-19 |
| Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy Brolucizumab 6 mg, Panretinal photocoagulation laser - Proliferative Diabetic Retinopathy | Phase 3 | Completed | Novartis Pharmaceuticals | 689 | 2020-11-19 | 2025-10-16 |
Showing 20 of 104. Sign in to see all of them.
Vitreous Hemorrhage (12) · Diabetic Retinopathy (10) · Diabetes Mellitus (5) · Macular Edema (5) · Retinal Perforations (5) · Epiretinal Membrane (3) · Macular Degeneration (3) · Cataract (2) · Diabetes Mellitus, Type 2 (2) · Disease (2) · Glaucoma, Neovascular (2) · Retinal Neovascularization (2) · Retinal Vein Occlusion (2) · Agnosia (1) · Diabetes Mellitus, Type 1 (1)
Eye Diseases (42) · Retinal Diseases (28) · Pathological Conditions, Signs and Symptoms (19) · Pathologic Processes (17) · Endocrine System Diseases (14) · Cardiovascular Diseases (12) · Eye Hemorrhage (12) · Vascular Diseases (12) · Hemorrhage (11) · Diabetes Complications (10) · Diabetic Angiopathies (10) · Diabetes Mellitus (9) · Retinal Degeneration (8) · Glucose Metabolism Disorders (7) · Metabolic Diseases (7)
Ranibizumab (17) · Bevacizumab (15) · Vitrectomy (9) · KH902 fusion protein (6) · aflibercept (6) · salicylhydroxamic acid (5) · Triamcinolone Acetonide (3) · pegaptanib (3) · Blood Specimen Collection (2) · Calcium Dobesilate (2) · Dexamethasone (2) · Lasers (2) · Adrenal Cortex Hormones (1) · Bupivacaine (1) · Control Groups (1)
Asociación para Evitar la Ceguera en México (8) · National Taiwan University Hospital (8) · Jaeb Center for Health Research (4) · Kyorin University (4) · Peking University People's Hospital (3) · University of Sao Paulo (3) · Anders Kvanta (2) · Cairo University (2) · JUNYAN ZHANG (2) · Odense University Hospital (2) · Ruijin Hospital (2) · Southeast Retina Center, Georgia (2) · Sun Yat-sen University (2) · Tianjin Medical University Eye Hospital (2) · Valley Retina Institute (2)
United States (25) · China (18) · Mexico (11) · Taiwan (9) · Brazil (5) · Japan (5) · Canada (3) · Denmark (3) · India (3) · Sweden (3) · Austria (2) · Egypt (2) · Italy (2) · South Korea (2) · Switzerland (2)
Chung-May Yang, MD (6) · Hugo Quiroz-Mercado, MD (4) · Makoto Inoue, MD (3) · Anders Kvanta, PhD (2) · Jinfeng Qu, MD (2) · Raul Velez-Montoya, MD (2) · Ursula Schmidt-Erfurth, MD (2) · Virgilio Morales-Canton, MD (2) · Abdhish Bhavsar, MD (1) · Adam R. Glassman, MS (1) · Ahmed A Abdel-Kader, MD, PhD (1) · Ahmed A Mohalhal, MD, PhD (1) · Alexander J. Brucker, M.D. (1) · Ameen Marashi, MD (1) · Andrew Antoszyk, MD (1)
PMID 26565927, PMID 32584384, PMID 37260074, PMID 15564755, PMID 17804919, PMID 19584650, PMID 20008710, PMID 20135139, PMID 20332654, PMID 20416952, PMID 20427088, PMID 20572497, PMID 21278146, PMID 21438852, PMID 21459214, PMID 21571677, PMID 21860693, PMID 22080911, PMID 22176513, PMID 22250209, PMID 22330964, PMID 22457045, PMID 22737347, PMID 22737351, PMID 22848140, PMID 22956609, PMID 22999634, PMID 23370902, PMID 23686001, PMID 24339677, PMID 24379924, PMID 24441951, PMID 24768239, PMID 25439614, PMID 25892934, PMID 26202442, PMID 26338819, PMID 26605370, PMID 26802783, PMID 26903223, PMID 28114569, PMID 28168567, PMID 28273240, PMID 28498374, PMID 31139483, PMID 31227330, PMID 31256030, PMID 31917731, PMID 32411431, PMID 32427087
U10EY014231 (2), U10EY018817 (2), 8UL1TR000128-07 (1), U10EY014229 (1)